



TECH CENTER 1600/2900

#17
#8
09/17/01
RECEIVED
SEP 14 2001

In re application of: HU et al.

Application Serial No.: 09/257,272

Art Unit: 1647

Filed: February 25, 1999

Examiner: Saoud, C.

For: Vascular Endothelial Growth Factor 2

Attorney Docket No.: PF112P2D2

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111 TO PAPER NO. 8

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the communication mailed May 24, 2001 (Paper No. 14), Applicants hereby request that the Examiner's rejections be removed in light of the remarks enclosed herein. Applicants submit concurrently herewith: (a) a Petition for Extension of Time for three (3) months up to and including September 24, 2001; and (b) a Fee Transmittal, with appropriate fee(s).

Remarks

Claims 22-32 have been cancelled and claims 33-400 are pending in this application. Applicants respectfully request that the method claims embedded in claims 33-400 remain pending in view of the following remarks. Applicants respectfully request reconsideration of the rejections in view of the following remarks.

In the Official Action of September 25, 2000 (Paper No. 8), the Examiner initially rejected claims 33-400 under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants